Organogenesis Holdings Inc (ORGO) Stock Price, Quote & News

Company Profile

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 781 575 0775

Website: organogenesis.com

Address:

85 Dan Road, Canton, United States

TimeForBio Feb. 20 at 3:55 PM

$ORGO Added. According to guidance the report should be very good

0 · Reply

AnonMav Feb. 19 at 4:15 PM

$ORGO 👋 https://share.trendspider.com/chart/ORGO/94993tnrlsf?_go=anonmav

0 · Reply

OfficialStocktwitsUser Feb. 18 at 4:36 PM

$ORGO RSI: 50.39, MACD: -0.1629 Vol: 0.13, MA20: 3.89, MA50: 4.42 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

UgoGreg Feb. 16 at 9:49 PM

$ORGO https://youtu.be/ygBN8MilTyc

0 · Reply

LarryPoormon199 Feb. 11 at 4:13 PM

$ORGO Organogenesis Holdings; regenerative medicine (wound care, ortho); commercial-stage; competitive pricing, reimbursement pressure.

0 · Reply

Monticello4 Feb. 10 at 8:34 PM

$ORGO ...

0 · Reply

Monticello4 Feb. 4 at 4:41 PM

$ORGO .

0 · Reply

Monticello4 Feb. 4 at 4:02 PM

$ORGO .

0 · Reply

Monticello4 Feb. 3 at 9:35 PM

$ORGO

0 · Reply

Monticello4 Feb. 3 at 9:17 PM

$ORGO ...

0 · Reply

Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2025 Financial Results on February 26, 2026

Dec 23, 2025, 4:05 PM EST - 2 months ago

Organogenesis Announces Initiation of Biologics License Application for ReNu®

Dec 15, 2025, 4:25 PM EST - 2 months ago

Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis Pain

Dec 11, 2025, 7:26 AM EST - 2 months ago

Organogenesis: High-Tech Skin Substitute Company On Sale

Nov 7, 2025, 4:36 PM EST - 3 months ago

Organogenesis Holdings Inc. (ORGO) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 4:05 PM EST - 3 months ago

Organogenesis Holdings Inc. Reports Third Quarter 2025 Financial Results, Posts Record Revenue and Raises 2025 Guidance

Nov 3, 2025, 1:10 PM EST - 3 months ago

Organogenesis Applauds CMS's Significant Step In Payment Reform

Oct 31, 2025, 4:05 PM EDT - 4 months ago

Organogenesis Holdings Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 17, 2025, 2:20 PM EDT - 4 months ago

Organogenesis Holdings Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – ORGO

Oct 1, 2025, 4:05 PM EDT - 5 months ago

Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2025 Financial Results on November 6, 2025

Sep 29, 2025, 8:26 AM EDT - 5 months ago

Organogenesis: Mixed ReNu Data, But Policy Tailwinds And Growth Remain Bullish

Sep 26, 2025, 11:24 AM EDT - 5 months ago

Why Is Organogenesis Stock Trading Lower Friday?

Sep 25, 2025, 4:50 PM EDT - 5 months ago

Organogenesis Provides Update on Second Phase 3 ReNu® Study

Aug 27, 2025, 4:05 PM EDT - 6 months ago

Organogenesis Holdings Inc. to Participate in Upcoming Investor Conferences in September

Aug 8, 2025, 6:30 PM EDT - 7 months ago

Organogenesis Holdings Inc. (ORGO) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:05 PM EDT - 7 months ago

Organogenesis Holdings Inc. Reports Second Quarter 2025 Financial Results

Jul 22, 2025, 4:05 PM EDT - 7 months ago

Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2025 Financial Results on August 7, 2025

Jul 15, 2025, 9:00 AM EDT - 7 months ago

Organogenesis Applauds CMS Proposal to Reform Skin Substitute Payment Policy; Urges Refinements to Ensure Patient Access to Appropriate Products and Continued Innovation

Jun 9, 2025, 5:39 PM EDT - 9 months ago

Organogenesis Holdings: ReNu And New LCD Offer A Rebound Scenario

May 11, 2025, 10:14 AM EDT - 10 months ago

Organogenesis Holdings Inc. (ORGO) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:05 PM EDT - 10 months ago

Organogenesis Holdings Inc. Reports First Quarter 2025 Financial Results

Apr 11, 2025, 4:05 PM EDT - 11 months ago

Organogenesis Supports CMS' Local Coverage Determination Implementation Delay to Review Coverage Policies to Maintain Patient Access with High Quality Evidence of Effectiveness

Apr 7, 2025, 4:05 PM EDT - 11 months ago

Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2025 Financial Results on May 8, 2025

Feb 27, 2025, 8:27 PM EST - 1 year ago

Organogenesis Holdings Inc. (ORGO) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 4:05 PM EST - 1 year ago

Organogenesis Holdings Inc. Reports Fourth Quarter 2024 Financial Results

Jan 27, 2025, 7:30 AM EST - 1 year ago

Organogenesis Holdings Inc. to Report Fourth Quarter of Fiscal Year 2024 Financial Results on February 27, 2025

Nov 22, 2024, 4:05 PM EST - 1 year ago

Organogenesis Expands Manufacturing Capacity to Support Future Growth

Nov 15, 2024, 9:25 AM EST - 1 year ago

Organogenesis Commends Final LCDs

Nov 12, 2024, 11:02 PM EST - 1 year ago

Organogenesis Holdings, Inc. (ORGO) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 4:01 PM EST - 1 year ago

Organogenesis Holdings Inc. Announces $130 Million Private Placement Offering of Series A Convertible Preferred Stock

Nov 11, 2024, 5:05 PM EST - 1 year ago

Organogenesis Reports Positive Interim Analysis of Second Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis

Oct 16, 2024, 7:30 AM EDT - 1 year ago

Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2024 Financial Results on November 12, 2024

Oct 1, 2024, 4:05 PM EDT - 1 year ago

Organogenesis Announces Publication of Randomized Clinical Trial Results Demonstrating the Safety and Efficacy of NuShield for Diabetic Foot Ulcers

Aug 8, 2024, 11:08 PM EDT - 1 year ago

Organogenesis Holdings, Inc. (ORGO) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 4:04 PM EDT - 1 year ago

Organogenesis Shares ReNu® Program Update

Jul 15, 2024, 4:05 PM EDT - 1 year ago

Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2024 Financial Results on August 8, 2024

Jun 6, 2024, 4:05 PM EDT - 1 year ago

Organogenesis Holdings Inc. to Participate in the Truist Securities MedTech Conference

May 9, 2024, 9:01 PM EDT - 1 year ago

Organogenesis Holdings, Inc. (ORGO) Q1 2024 Earnings Call Transcript

May 2, 2024, 7:00 AM EDT - 1 year ago

Organogenesis Achieves Primary Endpoint in Phase 3 Clinical Trial of ReNu® for Knee Osteoarthritis

Apr 16, 2024, 7:30 AM EDT - 2 years ago

Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2024 Financial Results on May 9, 2024

Feb 29, 2024, 11:06 PM EST - 2 years ago

Organogenesis Holdings, Inc. (ORGO) Q4 2023 Earnings Call Transcript

Feb 29, 2024, 4:05 PM EST - 2 years ago

Organogenesis Holdings Inc. Reports Fourth Quarter 2023 and Fiscal Year 2023 Financial Results; Introduces Fiscal Year 2024 Guidance

Feb 12, 2024, 7:30 AM EST - 2 years ago

Organogenesis Holdings Inc. to Participate in the BTIG Snowbird MedTech, Digital Health, Life Science and Diagnostic Tools Conference

Feb 8, 2024, 4:05 PM EST - 2 years ago

Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 29, 2024

Nov 9, 2023, 10:16 PM EST - 2 years ago

Organogenesis Holdings, Inc. (ORGO) Q3 2023 Earnings Call Transcript

Nov 9, 2023, 4:05 PM EST - 2 years ago

Organogenesis Holdings Inc. Reports Third Quarter 2023 Financial Results

TimeForBio Feb. 20 at 3:55 PM

$ORGO Added. According to guidance the report should be very good

0 · Reply

AnonMav Feb. 19 at 4:15 PM

$ORGO 👋 https://share.trendspider.com/chart/ORGO/94993tnrlsf?_go=anonmav

0 · Reply

OfficialStocktwitsUser Feb. 18 at 4:36 PM

0 · Reply

UgoGreg Feb. 16 at 9:49 PM

$ORGO https://youtu.be/ygBN8MilTyc

0 · Reply

LarryPoormon199 Feb. 11 at 4:13 PM

$ORGO Organogenesis Holdings; regenerative medicine (wound care, ortho); commercial-stage; competitive pricing, reimbursement pressure.

0 · Reply

Monticello4 Feb. 10 at 8:34 PM

$ORGO ...

0 · Reply

Monticello4 Feb. 4 at 4:41 PM

$ORGO .

0 · Reply

Monticello4 Feb. 4 at 4:02 PM

$ORGO .

0 · Reply

Monticello4 Feb. 3 at 9:35 PM

$ORGO

0 · Reply

Monticello4 Feb. 3 at 9:17 PM

$ORGO ...

0 · Reply

Mobagri Feb. 3 at 8:28 PM

$ORGO Mimedyx crashing. That’s why ORGO has creeped up last few days.

0 · Reply

Mobagri Feb. 3 at 3:06 PM

$ORGO Fuckin Monticello is wrong again, I’m surprised he still has a job at Mimedyx. That stock hit all time low

1 · Reply

Monticello4 Jan. 30 at 3:28 PM

$ORGO ...

0 · Reply

Monticello4 Jan. 29 at 3:32 PM

$ORGO ...

0 · Reply

Mobagri Jan. 28 at 6:28 PM

$ORGO Mimedyx being wiped out.

0 · Reply

Monticello4 Jan. 28 at 10:49 AM

$ORGO ...

0 · Reply

Monticello4 Jan. 27 at 2:34 PM

$ORGO ....

0 · Reply

Monticello4 Jan. 23 at 7:18 PM

$ORGO ...🙃

0 · Reply

Mobagri Jan. 23 at 5:48 PM

$ORGO heard from reps doctors are switching from Epifix to PuraPly. Seems correct

0 · Reply

Monticello4 Jan. 23 at 4:27 PM

$ORGO ...oh well...

0 · Reply

Mobagri Jan. 22 at 3:14 PM

$ORGO don’t regret being late

0 · Reply

Mobagri Jan. 22 at 2:42 PM

$ORGO bargain price. Once company announces positive news this will shoot back to $6. This happened three times last year

0 · Reply

Market Cap	505.11M
Revenue (ttm)	482.04M
Net Income (ttm)	860,000.00
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	21.33
Profit Margin	0.18%
Debt to Equity Ratio	0.00

Volume	355,000
Avg Vol	992,938
Day's Range	N/A - N/A
Shares Out	126.91M
Stochastic %K	74%
Beta	1.46
Analysts	Strong Sell
Price Target	$8.50